Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer

Short report

Ricardo Moreno, Pamela O Delgado, Patr?cia G Coelho, Sarah R Marsicano, Viviane A Boas, Ligia A Azzalis, Virg?nia B Junqueira, Katya C Rocha, Luiz Carlos de Abreu, Vitor E Valenti, Jefferson Drezzet, Edimar Cristiano Pereira and Fernando L Fonseca

For all author emails, please log on.

International Archives of Medicine 2013, 6:2?doi:10.1186/1755-7682-6-2

Published: 12 January 2013

Abstract (provisional)

Background

Several studies seek biological markers that give diagnostic and degree of tumor development. The aim of this study was to validate the determination of plasma DNA using nanotechnology (NanovueTM-NV) in samples of 80 patients with prostate cancer.

Methods

Blood samples of 80 patients of the Urology Ambulatory of Faculdade de Medicina do ABC with prostate cancer confirmed by anatomical-pathology criteria were analyzed. DNA extraction was performed using a GFX TM kit (Amersham Pharmacia Biotech, Inc, USA) following the adapted protocol. Plasma was subjected to centrifugation.

Results

There was a big difference between the first and the second value obtained by NanoVue Only two samples had no differences between duplicates. Maximum difference between duplicates was 38 mug/mL. Average variation between 51 samples was 10.29 mug/mL, although 21 samples had differences above this average. No correlation was observed between pDNA obtained by traditional spectrophotometry and by nanotechnology.

Conclusion

Determination of plasma DNA by nanotechnology was not reproducible.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Source: http://www.intarchmed.com/content/6/1/2

phil davis george st pierre aldon smith friday night lights nick santino bruce arians the misfits